Pre-exposure prophylaxis (PrEP) with oral antiretroviral medication is a highly effective and evidence-based HIV prevention method.  Despite its high clinical efficacy, efforts to expand the use of oral PrEP in EU/EEA countries have not fully realised its potential as part of combination prevention due to a variety of factors related to accessibility, affordability, and acceptability.

In this year’s report, Transgender Europe gives an overall assessment of how the strategy is delivering (or not) for trans people in the EU, as well as an update of what has been achieved toward the biggest highlights that we identified in our last report. We also include examples of how TGEU has been supporting the implementation of the strategy and our recommendations. Finally, we comment on other features of the strategy that were highlighted in our last report and present a table of main pieces of legislation and their status.

HIV transmission remains a major public health concern and affects more than 2.3 million people in the WHO European Region, particularly in the Eastern part of the Region. This report is the latest in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that has been reporting data on HIV and AIDS in the WHO European Region and in the European Union and European Economic Area (EU/EEA) since 2007.